头颈部肿瘤教学文稿.ppt

;流行病学;病因;HPV+口咽部肿瘤的疗效和生存情况 均比HPV- 的肿瘤要好;Human?papillomavirus?and?survival?of?patients?with?oropharyngeal cancer. N Engl J Med.?2010 Jul 1;363(1):24-35.;头颈部肿瘤特点;不同部位特点不同;分期;治疗特点;新辅助治疗;放疗;化疗;靶向治疗;;;不良预后因素;复发和(或)转移;Induction Chemotherapy;;;;Induction-chemotherapy arm vs. Surgery arm;TPF vs. PF;Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol.?2011;12(2):153-9;;hypopharyngeal and laryngeal;Long-term results of GORTEC 2000-01: A multicentric randomized phase III trial of induction chemotherapy with cisplatin plus 5-fluorouracil, with or without docetaxel, for larynx preservation. France 213 pts Median follow-up 105 months TPF vs. PF The 5- and 10-year larynx preservation rates 74.0% vs. 58.1% 70.3% vs. 46.5% The 5- and 10-year LDFFS rates 67.2% vs. 46.5% 63.7% vs. 37.2% OS, PFS no difference (LDFFS :larynx dysfunction-free survival) ;Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety. Springerplus.?2015;4:208. 7 randomized clinical (mata analysis) TPF vs. PF 3-year OS rate (HR: 1.14; 95% CI: 1.03 to 1.25; P?=?0.008) 3-year PFS rate (HR: 1.24; 95% CI: 1.08 to 1.43; P?=?0.002) 5-year OS rate (HR: 1.30; 95% CI, 1.09 to 1.55;P?=?0.003) 5-year PFS rate (HR: 1.39; 95% CI, 1.14 to 1.70; P?=?0.001) The TPF induction chemotherapy improved PFS and OS compared with PF ;;Induction Chemotherapy  vs. Concurrent ChemoRT;Long-Term Results of RTOG 91-11: A Comparison of ThreeNonsurgical Treatment Strategies to Preserve the Larynx in